Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MBIO with free AI briefings, catalyst countdowns, and dilution alerts.

MBIO · MUSTANG BIO, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$14.3M Cash on Hand
46.5mo Cash Runway
Follow MBIO by email Get an email when MBIO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MBIO, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Chimeric Antigen Receptor T-cells Recurrent B-Cell Non-Hodgkin Lymphoma Phase 1/2 · NCT03277729 Active not recruiting
Fludarabine Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Phase 1/2 · NCT04109482 Terminated
Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressin… Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Phase 1/2 · NCT04109482 Terminated
Autologous Anti-CD20CAR-CD28-4-1BB-CD3zeta… Follicular B-cell Non-Hodgkin's Lymphoma Phase 1/2 · NCT05360238 Terminated
Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressin… Adult Acute Myeloid Leukemia in Remission Phase 1 · NCT02159495 Active not recruiting
Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressin… Adult Acute Myeloid Leukemia in Remission Phase 1 · NCT02159495 Active not recruiting
Prior MB-102 CAR-T cell investigational product. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) N/A · NCT05645744 Terminated
Prior MB-106 CAR-T cell investigational product. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) N/A · NCT05645744 Terminated

Also used in these trials (approved or third-party drugs, not MBIO's own candidates): Cyclophosphamide, Fludarabine Phosphate.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MBIO holds $14.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $921,500/quarter from operations, an estimated runway of 46.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MBIO files for a raise →

👥 Who Owns MBIO

Insiders 2.2% Institutions (28 holders) 9.5% Public and other holders 88.3%
HolderTypeShares% of sharesAs of
Fortress Biotech, Inc.
10% owner
Insider 536,577 2.15% 2026-01-02
Peter Carney
Interim Chief Accounting Officer, Exhibi
Insider 3,992 0.02% 2023-12-11
Manuel MD Litchman
President, CEO and Interim CFO, Director
Insider 1,615 0.01% 2026-04-24
Adam J. Chill
Director
Insider 375 0.00% 2025-12-30
David Jin
Director
Insider 286 0.00% 2025-12-30
Neil Herskowitz
Director
Insider 145 0.00% 2025-12-30

Share count 24,976,289 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MBIO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MBIO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.